Author’s response to reviews

Title: Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study

Authors:

Ruihua Xu (xurh@sysucc.org.cn)
Xianjun Yu (yuxianjun@fudanpci.org)
Juhui Hao (jihuihao@yahoo.com)
Liwei Wang (syzlkgcp@163.com)
Hongming Pan (shonco@sina.cn)
Guohong Han (hangh@fmmu.edu.cn)
Jianming Xu (jmxu2003@yahoo.com)
Yanqiao Zhang (yanqiaozhang@126.com)
Shujun Yang (nkyang@126.com)
Jia Chen (chenjia@medmail.com.cn)
Jieer Ying (jieerying@aliyun.com)
Guanghai Dai (daigh2014@163.com)
Mingyu Li (mli@celgene.com)
Damir Begic (dbegic@celgene.com)
Brian Lu (blu@celgene.com)
Lin Shen (melanie.blanchard@meditechmedia.com; linshenpku@163.com)

Version: 4 Date: 12 Jul 2017

Author’s response to reviews:
Dear Editors:

Thank you for the opportunity to revise this manuscript to address the additional reviewer’s comments. We have made every effort to address each comment. Please see below for a detailed description of how each comment was addressed. Per your instructions to submit a clean version of the manuscript at this time, we did not track/highlight any changes to the manuscript.

Reviewer #1:

Comment 1: Please include the trial registration date at the end of the abstract, as per our submission guidelines.

We have added the trial registration number and date to the end of the abstract (p 3, line 64).

Comment 2: In the Ethics approval and consent to participate section, please provide the full names of all IRBs which approved your study protocol and detail whether informed consent which was obtained from all participants was written or verbal. If the IRBs are too numerous to list in this section, please provide their names in an additional file and list only the main IRB in this section, citing the additional file for the names of all IRBs.

We have provided the full names of all IRBs which approved the study protocol, and we specified that written consent was obtained from all participants (p 15, lines 332 - 340).

Comment 3: The individual contributions of ALL authors to the manuscript should be specified in the Authors’ Contributions section.

The individual contributions of all authors have been added to the manuscript in the Authors’ Contributions section (p 16, lines 355 - 357).

Comment 4: Thank you for providing a statement regarding the Availability of data and materials. However, we cannot currently accept the information provided as it does not meet our editorial policies (see http://www.biomedcentral.com/getpublished/editorial-policies#DataandMaterialRelease). Submission of a manuscript to a BioMed Central journal implies that materials described in the manuscript, including all relevant raw data, will be freely available to any scientist wishing to use them for non-commercial purposes, without breaching participant confidentiality. Please detail where the raw data supporting your findings can be
found (including information found in any supplementary files). If the raw data is publicly available or can be requested, please state that this is the case, and where the data can be found/requested from. Alternatively, if you do not wish to/cannot share your data, please state (in the ‘Availability of data and Materials’ section) that data will not be shared, and state the reason.

A statement has been added to the ‘Availability of data and Materials’ section regarding data availability (p 16, lines 346 - 347).

Best regards,

Lin Shen